Featured Press Releases

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

MilliporeSigma receives the industry

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

  • 03 Sep 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany,...

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Elizabeth Nanouris Named VP of Business Operations at InFocus Clinical Research

Elizabeth Nanouris Named VP of Business Operations at InFocus Clinical Research

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

  • PHC Corporation
  • 08 Sep 2026
Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

  • Release Versions
  • 07 Sep 2026
New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

  • SQ Innovation
  • 02 Sep 2026
Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

  • Jarrow Formulas
  • 02 Sep 2026
Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

  • Abbott
  • 01 Sep 2026
Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

  • Karyopharm Therapeutics Inc.
  • 31 Aug 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.